- Home
- RMI vs INMB Comparison
RMI vs INMB Comparison
Compare RMI & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RMI | INMB |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.3M | 64.7M |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RMI | INMB |
|---|---|---|
| Price | $14.40 | $2.39 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.40 |
| AVG Volume (30 Days) | 10.2K | ★ 322.7K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 257.14 |
| 52 Week Low | $14.06 | $1.09 |
| 52 Week High | $16.36 | $2.60 |
Technical Indicators
Market Signals| Indicator | RMI | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 44.54 | 54.39 |
| Support Level | $14.34 | $2.21 |
| Resistance Level | $14.80 | $2.55 |
| Average True Range (ATR) | 0.22 | 0.15 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 51.69 | 58.27 |
Price Performance
Historical ComparisonAbout RMI RiverNorth Opportunistic Municipal Income Fund Inc.
RiverNorth Opportunistic Municipal Income Fund, Inc. is a diversified, closed-end management investment company. Its investment objective is to seek current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.